Parenchymal border macrophages regulate CSF flow dynamics

• Published in: Nature (London) Vol. 611; no. 7936; pp. 585 - 593
• Main Authors: Drieu, Antoine, Du, Siling, Storck, Steffen E., Rustenhoven, Justin, Papadopoulos, Zachary, Dykstra, Taitea, Zhong, Fenghe, Kim, Kyungdeok, Blackburn, Susan, Mamuladze, Tornike, Harari, Oscar, Karch, Celeste M., Bateman, Randall J., Perrin, Richard, Farlow, Martin, Chhatwal, Jasmeer, Hu, Song, Randolph, Gwendalyn J., Smirnov, Igor, Kipnis, Jonathan
• Format: Journal Article
• Language: English
• Published: 01-11-2022
• ISSN: 0028-0836; 1476-4687
• DOI: 10.1038/s41586-022-05397-3

Macrophages are important players for the maintenance of tissue homeostasis
1
. Perivascular and leptomeningeal macrophages reside in close proximity to the central nervous system (CNS) parenchyma
2
, and their role in CNS physiology has not been well enough studied to date. Given their continuous interaction with the cerebrospinal fluid (CSF) and strategic positioning, we refer to these cells collectively as parenchymal border macrophages (PBMs). Here, we demonstrate that PBMs regulate CSF flow dynamics. We identify a subpopulation of PBMs expressing high levels of CD163 and Lyve1 (scavenger receptor proteins), located in close proximity to the brain arterial tree, and show that Lyve1+ PBMs regulate arterial motion that drives CSF flow. Pharmacological or genetic depletion of PBMs led to accumulation of extracellular matrix proteins, obstructing CSF access to perivascular spaces hence impairing CNS perfusion and clearance. Aging-associated alterations in PBMs and impairment of CSF dynamics were restored upon intracisternal injection of macrophage colony-stimulating growth factor (M-CSF). Human single-nuclei RNA sequencing data obtained from Alzheimer’s disease (AD) patients and healthy controls point to changes in phagocytosis/endocytosis and interferon-gamma (IFNγ) signaling on PBMs, pathways that are corroborated in a mouse AD model. Collectively, our results identify PBMs as novel cellular regulators of CSF flow dynamics, which could potentially be targeted pharmacologically to alleviate brain clearance deficits associated with aging and AD.